Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Braizon Therapeutics

Request full access

Nanotechnology drug delivery platform for CNS diseases

Tokyo, JapanFounded 2015Biotech & Life Sciences

About Braizon Therapeutics

Braizon Therapeutics, Inc. is a Japanese biotechnology company established on October 30, 2015, that is developing a drug delivery system (DDS) to overcome the blood-brain barrier (BBB). The company's core technology, Brain Access®, is a platform that uses nanoparticles to transport therapeutic compounds to the central nervous system (CNS) to treat diseases like Alzheimer's. The company was founded by venture capital group Fast Track Initiative. Its founding technology was the result of a collaboration between Professor Kazunori Kataoka of the University of Tokyo and Professor Takanori Yokota of the Tokyo Medical and Dental University. Mariko Tosu is a founder and previously served as CEO, with Philip Davy currently holding the CEO position.

The company's primary focus is on addressing the challenge of delivering drugs to the brain, which is protected by the highly selective BBB. Braizon's technology encapsulates drugs within glucose-labeled nanoparticles, or micelles, which can cross the BBB. The company is also developing a second-generation system that utilizes the transferrin receptor (TfR) pathway, which would not require glycemic control. This platform is versatile and can carry various therapeutic molecules, including nucleic acid medicines, antibodies, and low-molecular-weight compounds.

Braizon Therapeutics' business model centers on licensing its Brain Access® platform to pharmaceutical and biotechnology companies, as well as academic institutions. These partners can then use the technology to develop new therapies for CNS disorders. The company also has its own pipeline of treatments in development. Braizon has research and development divisions in Kawasaki, Japan, and Cambridge, Massachusetts, USA. Since its founding, the company has secured funding from investors including Fast Track Initiative, The University of Tokyo Cooperative Platform Development Co., Ltd., and SMBC Venture Capital Co., Ltd. In March 2016, the company raised 106 million yen in a Series A round, followed by a Series B round of 645 million yen in July 2018. Another funding round in July 2021 brought in 300 million yen.

Source: Dealroom company data

Braizon Therapeutics in the Tokyo ecosystem

Live from Dealroom

The Braizon Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • Fast Track Initiative
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States33.3%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Braizon Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Braizon Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.